Selected research
Industry Research
Immunotoxins Industry Research Report 2026
Market perspective
The global Immunotoxins market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Immunotoxins is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Immunotoxins is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Immunotoxins is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Immunotoxins include Bayer HealthCare, Amgen, Research Corporation Technologies, Neurocrine Biosciences, Genmab, Genentech, CuraGen Corporation, Celldex Therapeutics and Biotest, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Immunotoxins market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Immunotoxins Market by Company
Bayer HealthCare
Amgen
Research Corporation Technologies
Neurocrine Biosciences
Genmab
Genentech
CuraGen Corporation
Celldex Therapeutics
Biotest
AREVA Med
Immunotoxins Segment by Type
Diphtheria Toxin (DT) & DT Derivatives
Ribonucleases based Immunotoxins
Pseudomonas Exotoxin (PE) & PE Derivatives
Anthrax Based Toxins
Ribosome Inactivating Proteins Based Immunotoxins
Others
Immunotoxins Segment by Application
Solid Tumors
Leukemias
Immunotoxins Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immunotoxins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immunotoxins and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immunotoxins.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Immunotoxins manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Immunotoxins by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Immunotoxins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Diphtheria Toxin (DT) & DT Derivatives
- Ribonucleases based Immunotoxins
- Pseudomonas Exotoxin (PE) & PE Derivatives
- Anthrax Based Toxins
- Ribosome Inactivating Proteins Based Immunotoxins
- Others
Applications
- Solid Tumors
- Leukemias
Companies covered
- Bayer HealthCare
- Amgen
- Research Corporation Technologies
- Neurocrine Biosciences
- Genmab
- Genentech
- CuraGen Corporation
- Celldex Therapeutics
- Biotest
- AREVA Med
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Immunotoxins Market Size (2021-2032)
- 2.2.2 Global Immunotoxins Sales (2021-2032)
- 2.2.3 Global Immunotoxins Market Average Price (2021-2032)
- 2.3 Immunotoxins by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Diphtheria Toxin (DT) & DT Derivatives
- 2.3.3 Ribonucleases based Immunotoxins
- 2.3.4 Pseudomonas Exotoxin (PE) & PE Derivatives
- 2.3.5 Anthrax Based Toxins
- 2.3.6 Ribosome Inactivating Proteins Based Immunotoxins
- 2.3.7 Others
- 2.4 Immunotoxins by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Solid Tumors
- 2.4.3 Leukemias
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Immunotoxins Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Immunotoxins Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Immunotoxins Revenue of Manufacturers (2021-2026)
- 3.4 Global Immunotoxins Average Price by Manufacturers (2021-2026)
- 3.5 Global Immunotoxins Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Immunotoxins, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Immunotoxins, Product Type & Application
- 3.8 Global Manufacturers of Immunotoxins, Established Date
- 3.9 Global Immunotoxins Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bayer HealthCare
- 4.1.1 Bayer HealthCare Company Information
- 4.1.2 Bayer HealthCare Business Overview
- 4.1.3 Bayer HealthCare Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bayer HealthCare Immunotoxins Product Portfolio
- 4.1.5 Bayer HealthCare Recent Developments
- 4.2 Amgen
- 4.2.1 Amgen Company Information
- 4.2.2 Amgen Business Overview
- 4.2.3 Amgen Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Immunotoxins Product Portfolio
- 4.2.5 Amgen Recent Developments
- 4.3 Research Corporation Technologies
- 4.3.1 Research Corporation Technologies Company Information
- 4.3.2 Research Corporation Technologies Business Overview
- 4.3.3 Research Corporation Technologies Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Research Corporation Technologies Immunotoxins Product Portfolio
- 4.3.5 Research Corporation Technologies Recent Developments
- 4.4 Neurocrine Biosciences
- 4.4.1 Neurocrine Biosciences Company Information
- 4.4.2 Neurocrine Biosciences Business Overview
- 4.4.3 Neurocrine Biosciences Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Neurocrine Biosciences Immunotoxins Product Portfolio
- 4.4.5 Neurocrine Biosciences Recent Developments
- 4.5 Genmab
- 4.5.1 Genmab Company Information
- 4.5.2 Genmab Business Overview
- 4.5.3 Genmab Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Genmab Immunotoxins Product Portfolio
- 4.5.5 Genmab Recent Developments
- 4.6 Genentech
- 4.6.1 Genentech Company Information
- 4.6.2 Genentech Business Overview
- 4.6.3 Genentech Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genentech Immunotoxins Product Portfolio
- 4.6.5 Genentech Recent Developments
- 4.7 CuraGen Corporation
- 4.7.1 CuraGen Corporation Company Information
- 4.7.2 CuraGen Corporation Business Overview
- 4.7.3 CuraGen Corporation Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CuraGen Corporation Immunotoxins Product Portfolio
- 4.7.5 CuraGen Corporation Recent Developments
- 4.8 Celldex Therapeutics
- 4.8.1 Celldex Therapeutics Company Information
- 4.8.2 Celldex Therapeutics Business Overview
- 4.8.3 Celldex Therapeutics Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Celldex Therapeutics Immunotoxins Product Portfolio
- 4.8.5 Celldex Therapeutics Recent Developments
- 4.9 Biotest
- 4.9.1 Biotest Company Information
- 4.9.2 Biotest Business Overview
- 4.9.3 Biotest Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Biotest Immunotoxins Product Portfolio
- 4.9.5 Biotest Recent Developments
- 4.10 AREVA Med
- 4.10.1 AREVA Med Company Information
- 4.10.2 AREVA Med Business Overview
- 4.10.3 AREVA Med Immunotoxins Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AREVA Med Immunotoxins Product Portfolio
- 4.10.5 AREVA Med Recent Developments
5 Global Immunotoxins Market Scenario by Region
- 5.1 Global Immunotoxins Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Immunotoxins Sales by Region: 2021-2032
- 5.2.1 Global Immunotoxins Sales by Region: 2021-2026
- 5.2.2 Global Immunotoxins Sales by Region: 2027-2032
- 5.3 Global Immunotoxins Revenue by Region: 2021-2032
- 5.3.1 Global Immunotoxins Revenue by Region: 2021-2026
- 5.3.2 Global Immunotoxins Revenue by Region: 2027-2032
- 5.4 North America Immunotoxins Market Facts & Figures by Country
- 5.4.1 North America Immunotoxins Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Immunotoxins Sales by Country (2021-2032)
- 5.4.3 North America Immunotoxins Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Immunotoxins Market Facts & Figures by Country
- 5.5.1 Europe Immunotoxins Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Immunotoxins Sales by Country (2021-2032)
- 5.5.3 Europe Immunotoxins Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Immunotoxins Market Facts & Figures by Country
- 5.6.1 Asia Pacific Immunotoxins Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Immunotoxins Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Immunotoxins Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Immunotoxins Market Facts & Figures by Country
- 5.7.1 South America Immunotoxins Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Immunotoxins Sales by Country (2021-2032)
- 5.7.3 South America Immunotoxins Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Immunotoxins Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Immunotoxins Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Immunotoxins Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Immunotoxins Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Immunotoxins Sales by Type (2021-2032)
- 6.1.1 Global Immunotoxins Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Immunotoxins Sales Market Share by Type (2021-2032)
- 6.2 Global Immunotoxins Revenue by Type (2021-2032)
- 6.2.1 Global Immunotoxins Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Immunotoxins Revenue Market Share by Type (2021-2032)
- 6.3 Global Immunotoxins Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Immunotoxins Sales by Application (2021-2032)
- 7.1.1 Global Immunotoxins Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Immunotoxins Sales Market Share by Application (2021-2032)
- 7.2 Global Immunotoxins Revenue by Application (2021-2032)
- 7.2.1 Global Immunotoxins Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Immunotoxins Revenue Market Share by Application (2021-2032)
- 7.3 Global Immunotoxins Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Immunotoxins Value Chain Analysis
- 8.1.1 Immunotoxins Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Immunotoxins Production Mode & Process
- 8.2 Immunotoxins Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Immunotoxins Distributors
- 8.2.3 Immunotoxins Customers
9 Global Immunotoxins Analyzing Market Dynamics
- 9.1 Immunotoxins Industry Trends
- 9.2 Immunotoxins Industry Drivers
- 9.3 Immunotoxins Industry Opportunities and Challenges
- 9.4 Immunotoxins Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst